Brunner H R, Gavras H, Waeber B, Turini G A, McKinstry D N, Vukovich R A, Gavras I
Br J Clin Pharmacol. 1979;7 Suppl 2(Suppl 2):205S-211S. doi: 10.1111/j.1365-2125.1979.tb04692.x.
1 Captopril (SQ14,225), an orally active inhibitor of angiotensin-converting enzyme, was administered to nine patients with essential hypertension. Plasma renin activity (PRA) was low in four, 'normal' in three and high in two patients. 2 In the hospital, captopril alone induced a significant drop in BP from 165 +/- 6/106 +/- 2 to 140 +/- 5/90 +/- 1 mmHb (P less than 0.001). PRA increased concomitantly (P less than 0.05), whereas plasma-converting enzyme activity (P less than 0.005) and plasma aldosterone (P less than 0.05) were reduced. 3 Six patients underwent chronic ambulatory therapy with captopril for a mean of 16 +/- 3 weeks. After discharge from the hospital, BP remained normalized but in five out of six patients this required additional diuretic therapy. 4 The results suggest that captopril alone or combined with diuretic therapy provides a new, efficient and well tolerated tool to treat patients with essential hypertension independently of their PRA level. It may turn out to be more effective in lowering BP than beta-adrenoceptor-blocking agents.
卡托普利（SQ14,225），一种口服有效的血管紧张素转换酶抑制剂，被给予9例原发性高血压患者。4例患者血浆肾素活性（PRA）低，3例“正常”，2例高。
在医院里，单独使用卡托普利使血压从165±6/106±2显著降至140±5/90±1 mmHg（P<0.001）。PRA同时升高（P<0.05），而血浆转换酶活性（P<0.005）和血浆醛固酮（P<0.05）降低。
6例患者接受卡托普利慢性门诊治疗，平均16±3周。出院后，血压仍维持正常，但6例患者中有5例需要额外的利尿治疗。
结果表明，单独使用卡托普利或与利尿治疗联合使用，为治疗原发性高血压患者提供了一种新的、有效且耐受性良好的方法，与他们的PRA水平无关。它在降低血压方面可能比β-肾上腺素受体阻滞剂更有效。
